Business Context and Reporting Period
This Form 8-K Current Report was filed by Vanda Pharmaceuticals Inc. on September 8, 2011. The filing serves as a Regulation FD disclosure regarding a corporate presentation by President and CEO Mihael H. Polymeropoulos, M.D., at the Stifel Nicolaus Global Healthcare Conference in Boston, MA, held on the same date.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of an upcoming event and does not contain financial statements or operational results.
Material Changes
No material changes to financial condition or operations are reported in this document. The filing references a press release issued on August 31, 2011, announcing the company's participation in the conference.
Guidance, Outlook, and Risks
The presentation slides and verbal statements made during the conference contain forward-looking statements regarding the company's expectations. The filing explicitly disclaims any obligation to update these statements after the conference date.
Key risks and contingencies identified include:
- The extent and effectiveness of development, sales, and marketing support for the product Fanapt.
- Ability to commercialize Fanapt outside the U.S. and Canada.
- Delays in clinical trials or failure of products to be safe and effective.
- Failure to obtain regulatory approval or comply with ongoing requirements.
- Lack of market acceptance or failure to become profitable.
- Inability to obtain necessary capital for research and development.
- Loss of key scientists or management personnel.
- Product liability claims and loss of rights under license agreements.
Key Facts for Investor Verification
- Verify the content of the presentation slides (Exhibit 99.1) and the August 31, 2011 press release (Exhibit 99.2) for specific strategic updates.
- Review the most recent Form 10-K (fiscal year ended December 31, 2010) and Form 10-Q (quarter ended June 30, 2011) for actual financial data and detailed risk factors.
- Note that the company explicitly declines to update forward-looking statements made during the September 8, 2011 presentation.